MAP2K3 (Ab-189) Antibody

What is MAP2K3 and what are its main functional roles in signaling pathways?

MAP2K3 (also known as MEK3, MKK3, or PRKMK3) is a dual specificity protein kinase belonging to the MAP kinase kinase family. It functions primarily as a critical component in the MAP kinase-mediated signaling cascade, where it becomes activated by mitogenic stimulation and environmental stress. MAP2K3's principal function involves phosphorylating and activating MAPK14/p38-MAPK, thereby regulating downstream cellular responses to stress and cytokine signaling . As a dual specificity kinase, MAP2K3 catalyzes the concomitant phosphorylation of both threonine and tyrosine residues in the p38 MAP kinase, enabling proper signal transduction in response to environmental stimuli .

What are the technical specifications of MAP2K3 (Ab-189) Antibody?

The MAP2K3 (Ab-189) Antibody is a rabbit-derived polyclonal antibody designed to detect endogenous levels of total MAP2K3 protein, with specific emphasis on the region surrounding the S189 phosphorylation site. This antibody has a molecular weight of approximately 39kDa and demonstrates reactivity across multiple species including human, mouse, and rat samples . For storage stability, antibodies targeting MAP2K3 should typically be stored at -20°C or lower, with aliquoting recommended to avoid repeated freeze-thaw cycles that could compromise antibody integrity . When using this antibody for experimental applications, appropriate dilutions must be determined empirically for specific detection methods.

How can I validate the specificity of MAP2K3 (Ab-189) Antibody in my experimental system?

To validate MAP2K3 (Ab-189) Antibody specificity, implement a multi-approach strategy:

• Positive and negative controls: Compare antibody detection between MAP2K3-expressing cells and MAP2K3 knockout models generated using CRISPR/Cas9 technology. The antibody should produce a signal in wild-type cells but not in knockout cells .

• Western blot analysis: Confirm the detection of a single band at approximately 39kDa when analyzing cell lysates. Comparative analysis using different cell types with known MAP2K3 expression levels can further validate specificity .

• Phosphorylation state controls: For phospho-specific applications, compare detection between samples treated with phosphatase inhibitors versus phosphatase-treated samples to confirm phosphorylation state specificity .

• RNA interference: Conduct siRNA-mediated knockdown of MAP2K3 and observe corresponding reduction in antibody signal intensity. This approach, similar to methods described for MAP2K3 studies, provides functional validation of antibody specificity .

What are the optimal protocols for using MAP2K3 (Ab-189) Antibody in Western blotting experiments?

For optimal Western blotting with MAP2K3 (Ab-189) Antibody:

• Sample preparation:

  • Lyse cells in buffer containing phosphatase inhibitors if detecting phosphorylated forms

  • Include protease inhibitors to prevent protein degradation

  • Denature samples at 95°C for 5 minutes in sample buffer containing SDS and DTT

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation of the 39kDa MAP2K3 protein

  • Transfer to PVDF or nitrocellulose membranes at 100V for 60-90 minutes

• Antibody incubation:

  • Block membranes with 5% BSA in TBST for 1 hour at room temperature

  • Incubate with MAP2K3 (Ab-189) Antibody at 1:1000-1:2000 dilution overnight at 4°C

  • Wash 3x with TBST for 10 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody at 1:5000 dilution

• Detection:

  • Develop using enhanced chemiluminescence substrates

  • Expose to X-ray film or use digital imaging systems for detection

Expected results include a distinct band at approximately 39kDa, with potential variation based on post-translational modifications or isoform expression.

How can MAP2K3 (Ab-189) Antibody be effectively used in flow cytometry applications?

For flow cytometry applications using MAP2K3 (Ab-189) Antibody:

• Cell preparation:

  • Harvest cells using gentle detachment methods to preserve surface epitopes

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 or 90% methanol for intracellular staining

• Antibody staining:

  • Block with 5% normal serum in PBS for 30 minutes

  • Incubate with MAP2K3 (Ab-189) Antibody at recommended concentration (5 μL/10^6 cells or 0.05 μg/mL)

  • Wash cells twice with PBS containing 0.5% BSA

  • Incubate with appropriate fluorophore-conjugated secondary antibody

• Instrument settings:

  • Establish compensation controls for multi-color experiments

  • Include unstained and isotype controls to determine background fluorescence

  • Acquire sufficient events (minimum 10,000) for statistical significance

For phospho-specific detection, compare treated (e.g., UV+TPA stimulated) versus untreated cells to demonstrate activation-dependent phosphorylation, similar to the approach shown in flow cytometric analysis of HEK293T cells with phospho-specific antibodies .

What are the established methods for studying MAP2K3 function through gene knockout or knockdown approaches?

To investigate MAP2K3 function through genetic manipulation:

• CRISPR/Cas9 knockout:

  • Design sgRNAs targeting the MAP2K3 gene using established design tools

  • Transfect cells with sgRNA and Cas9 expression vectors

  • Select puromycin-resistant clones following transfection

  • Validate knockout by Western blot analysis and Sanger sequencing

  • Expand confirmed clones for functional studies

• siRNA knockdown:

  • Design or purchase validated siRNAs targeting MAP2K3 mRNA

  • Transfect cells using Lipofectamine RNAiMAX following manufacturer's protocols

  • Confirm knockdown efficiency by qRT-PCR and Western blot analysis 48-72 hours post-transfection

  • Proceed with functional assays after confirming successful knockdown

• Stable shRNA expression:

  • Generate lentiviral particles containing MAP2K3-targeting shRNA constructs

  • Infect target cells and select with appropriate antibiotics

  • Validate knockdown efficiency by qRT-PCR and Western blot

  • Use in long-term studies requiring sustained MAP2K3 suppression

These approaches have been successfully employed to investigate MAP2K3's role in various cellular processes, including its involvement in STAT3 signaling and tumor progression .

How can I investigate the interaction between MAP2K3 and MAP2K6 using proximity ligation assays?

To investigate MAP2K3-MAP2K6 interactions using proximity ligation assay (PLA):

• Sample preparation:

  • Culture cells on cover slips or chamber slides

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

  • Block with 5% BSA or Duolink blocking solution for 1 hour

• Primary antibody incubation:

  • Apply anti-MAP2K3 rabbit polyclonal antibody (1:1200 dilution) and anti-MAP2K6 mouse monoclonal antibody (1:50 dilution)

  • Incubate overnight at 4°C in a humidified chamber

  • Wash 3x with PBS or TBS containing 0.1% Tween 20

• PLA protocol:

  • Add PLA probes (anti-rabbit PLUS and anti-mouse MINUS)

  • Perform ligation and amplification steps according to manufacturer's protocol

  • Counterstain nuclei with DAPI

• Image analysis:

  • Acquire images using confocal or fluorescence microscopy

  • Analyze interaction signals (red dots) using specialized software like BlobFinder

  • Quantify interaction events per cell across multiple fields

This approach reveals protein-protein interactions between MAP2K3 and MAP2K6 as distinct red fluorescent dots, representing detection of interaction complexes within approximately 40nm distance, as demonstrated in HeLa cells .

What is the role of MAP2K3 in the miR-19b-3p-MAP2K3-STAT3 feedback loop, and how can I study this pathway?

The miR-19b-3p-MAP2K3-STAT3 feedback loop represents a complex regulatory mechanism in cancer biology, particularly in esophageal squamous cell carcinoma (ESCC). To study this pathway:

• Investigating MAP2K3-STAT3 interaction:

  • Implement co-immunoprecipitation assays using MAP2K3 (Ab-189) Antibody to pull down protein complexes

  • Analyze STAT3 levels and phosphorylation status by Western blotting

  • Employ proximity ligation assays to visualize MAP2K3-STAT3 interaction in situ

• Examining MAP2K3-mediated STAT3 degradation:

  • Conduct ubiquitination assays to assess STAT3 ubiquitination status in the presence/absence of MAP2K3

  • Utilize proteasome inhibitors (e.g., MG132) to confirm involvement of the ubiquitin-proteasome pathway

  • Investigate the role of MDM2 in this process through co-immunoprecipitation and knockdown studies

• miRNA regulation studies:

  • Transfect cells with miR-19b-3p mimics or inhibitors to modulate pathway activity

  • Assess MAP2K3 expression by qRT-PCR and Western blot following miRNA modulation

  • Conduct luciferase reporter assays using MAP2K3 3'UTR constructs to confirm direct targeting

  • Isolate exosomes from plasma of cancer patients to study exosomal miR-19b-3p effects on MAP2K3 expression

• Chromatin immunoprecipitation for transcriptional regulation:

  • Perform ChIP assays with anti-STAT3 antibodies to demonstrate STAT3 binding to the MIR19B promoter

  • Design appropriate primers for the MIR19B promoter region for qPCR analysis

  • Compare binding in different cellular contexts (e.g., MAP2K3 knockout vs. wild-type)

These methods will help elucidate how MAP2K3 suppresses STAT3 expression and activation, while STAT3 binds to the MIR19B promoter to increase miR-19b-3p expression, which in turn suppresses MAP2K3, completing the feedback loop .

How does mutant p53 regulate MAP2K3 expression, and what techniques can be used to study this relationship?

The regulatory relationship between mutant p53 and MAP2K3 can be investigated using these methodological approaches:

• Transcriptional regulation analysis:

  • Clone the MAP2K3 gene 5'-regulatory region (-989 to -2) into a luciferase reporter vector

  • Perform luciferase reporter assays in cells expressing wild-type p53, mutant p53 variants (R175H, R273H), or p53-null controls

  • Design appropriate primers for PCR amplification of the promoter region (e.g., MAP2K3-For: 5'-GAGCTCACCACCGACCC-3' and MAP2K3-Rev: 5'-TGCAAGTGGGTCCTGGAC-3')

• Chromatin immunoprecipitation (ChIP):

  • Conduct ChIP assays using anti-p53 antibodies to assess direct binding to the MAP2K3 promoter

  • Design primers for the MAP2K3 promoter region and negative control regions

  • Perform qPCR analysis of immunoprecipitated DNA to quantify binding enrichment

  • Compare binding between wild-type p53 and mutant p53 proteins

• Expression correlation studies:

  • Generate stable cell lines with inducible mutant p53 expression

  • Monitor MAP2K3 mRNA levels by qRT-PCR using primers such as hMAP2K3-For (5'-CCTTTAGGGATCTCGGGTTT-3') and hMAP2K3-Rev (5'-TCCCGCTCTCTGTCAAGTC-3')

  • Assess protein expression changes by Western blot analysis

  • Perform RNAi-mediated depletion of endogenous mutant p53 and measure effects on MAP2K3 expression

• Ectopic expression studies:

  • Transfect cells with plasmids expressing wild-type or mutant p53 variants

  • Generate stable transfectants using appropriate selection markers

  • Analyze MAP2K3 expression levels by Western blot and qRT-PCR

  • Perform functional assays to assess biological significance of the regulatory relationship

Research has demonstrated that mutant p53 proteins (particularly R175H and R273H variants) significantly upregulate MAP2K3 expression at both mRNA and protein levels, whereas wild-type p53 does not show this effect, suggesting a gain-of-function property of mutant p53 in regulating MAP2K3 .

What are the common technical challenges when using MAP2K3 (Ab-189) Antibody in immunoprecipitation experiments?

When conducting immunoprecipitation with MAP2K3 (Ab-189) Antibody, researchers may encounter these challenges and solutions:

• Low immunoprecipitation efficiency:

  • Optimize antibody concentration (typically 2-5 μg per sample)

  • Extend incubation time to overnight at 4°C with gentle rotation

  • Use protein A/G beads for rabbit polyclonal antibodies to improve capture efficiency

  • Pre-clear lysates with beads alone to reduce non-specific binding

• High background or non-specific binding:

  • Increase washing stringency using buffers with higher salt concentration

  • Add 0.1-0.5% NP-40 or Triton X-100 to wash buffers

  • Use BSA or non-fat dry milk (1-5%) in blocking and antibody dilution buffers

  • Consider crosslinking antibody to beads using dimethyl pimelimidate

• Protein complex dissociation:

  • Use gentler lysis conditions to preserve protein-protein interactions

  • Consider crosslinking interacting proteins prior to lysis

  • Supplement lysis buffers with protease and phosphatase inhibitors

  • Avoid harsh detergents that may disrupt protein complexes

• Detecting phosphorylated forms:

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride) in all buffers

  • Maintain samples at 4°C throughout processing

  • Use phospho-specific detection antibodies in Western blot analysis of immunoprecipitates

Remember that optimization of buffer conditions, antibody concentrations, and incubation times may be necessary depending on your specific experimental system and the nature of the interactions being studied.

How can I optimize detection of MAP2K3 phosphorylation states in different experimental conditions?

To optimize detection of MAP2K3 phosphorylation states:

• Stimulation protocols:

  • For maximal MAP2K3 activation, treat cells with appropriate stimuli (UV+TPA, cytokines, or environmental stressors)

  • Establish time-course experiments to determine optimal stimulation duration

  • Compare multiple activation methods to identify the most effective for your cell type

  • Include negative controls using specific inhibitors (e.g., K252a) to block activation

• Sample preparation:

  • Harvest cells rapidly to prevent phosphorylation changes during processing

  • Lyse cells directly in buffer containing strong phosphatase inhibitors

  • Add phosphatase inhibitor cocktails containing sodium orthovanadate, sodium fluoride, and β-glycerophosphate

  • Maintain samples at 4°C throughout processing

• Antibody selection and validation:

  • Use phospho-specific antibodies that recognize MAP2K3 phosphorylated at S189

  • Validate specificity using lambda phosphatase-treated versus untreated samples

  • Compare detection in stimulated versus unstimulated cells

  • Consider using dual phospho-specific antibodies that detect both MAP2K3 (S189) and MAP2K6 (S207) when appropriate

• Detection methods optimization:

  • For Western blotting: use PVDF membranes and block with 5% BSA rather than milk

  • For flow cytometry: optimize fixation and permeabilization protocols for intracellular phospho-epitopes

  • For immunofluorescence: evaluate different fixation methods to preserve phospho-epitopes

  • Include phosphorylation state controls in each experiment

Flow cytometry analysis comparing K252a-treated cells (inhibiting phosphorylation) versus UV+TPA-treated cells (stimulating phosphorylation) can effectively demonstrate the dynamic range of phosphorylation detection, as shown in the HEK293T cell analysis .

What are emerging applications of MAP2K3 (Ab-189) Antibody in cancer research and potential therapeutic targeting?

Emerging applications of MAP2K3 (Ab-189) Antibody in cancer research include:

• Biomarker development:

  • Evaluating MAP2K3 expression and phosphorylation status in tumor biopsies

  • Correlating MAP2K3 activation patterns with treatment response and patient outcomes

  • Developing diagnostic assays for stratifying patients based on MAP2K3 pathway activation

  • Monitoring treatment efficacy through changes in MAP2K3 phosphorylation status

• Therapeutic targeting strategies:

  • Identifying small molecule inhibitors of MAP2K3 kinase activity

  • Evaluating combination therapies targeting both MAP2K3 and STAT3 pathways

  • Exploring the potential of disrupting the miR-19b-3p-MAP2K3-STAT3 feedback loop

  • Developing approaches to modulate MAP2K3 expression in mutant p53-expressing tumors

• Exosome-based research:

  • Investigating exosomal miR-19b-3p as a liquid biopsy biomarker

  • Studying the role of exosome-mediated signaling in modulating MAP2K3 expression

  • Developing exosome-based therapeutic approaches targeting the MAP2K3 pathway

  • Evaluating exosomal content as predictors of treatment response

• Immunotherapy connections:

  • Exploring the relationship between MAP2K3 activation and tumor immune microenvironment

  • Investigating potential synergies between MAP2K3 inhibition and immune checkpoint blockade

  • Studying MAP2K3's role in regulating inflammatory signaling within the tumor microenvironment

  • Developing combination strategies targeting both MAP2K3 and immunomodulatory pathways

Recent findings demonstrating MAP2K3's role in ESCC tumorigenesis through the miR-19b-3p-MAP2K3-STAT3 feedback loop highlight the potential therapeutic value of targeting this pathway, particularly in cancers with dysregulated p53 function .

How might MAP2K3 antibodies be incorporated into multiparametric analysis systems for signaling pathway profiling?

Integration of MAP2K3 antibodies into multiparametric analysis systems offers powerful approaches for comprehensive signaling pathway profiling:

• Mass cytometry (CyTOF) applications:

  • Incorporate metal-conjugated MAP2K3 (Ab-189) Antibody into CyTOF panels

  • Develop multiparametric panels including upstream activators and downstream effectors

  • Simultaneously measure MAP2K3 activation alongside p38 MAPK, STAT3, and other pathway components

  • Correlate MAP2K3 activation with cellular phenotypes and functional readouts

• Multiplex immunoassay development:

  • Design bead-based multiplex assays including MAP2K3 and phospho-MAP2K3 detection

  • Create antibody pairs for sandwich ELISA formats in multiplex platforms

  • Develop assays measuring multiple nodes in the MAP kinase cascade simultaneously

  • Validate multiplexed detection across diverse sample types and experimental conditions

• Imaging-based multiparametric approaches:

  • Expand proximity ligation assay techniques to simultaneously detect multiple interaction partners

  • Develop multiplexed immunofluorescence panels incorporating MAP2K3 detection

  • Implement cyclic immunofluorescence or imaging mass cytometry for high-dimensional spatial analysis

  • Correlate MAP2K3 localization and activation with subcellular compartmentalization of signaling components

• Single-cell analysis platforms:

  • Adapt MAP2K3 antibodies for single-cell western blotting applications

  • Incorporate into microfluidic-based single-cell protein analysis systems

  • Combine with single-cell RNA sequencing for multi-omic profiling

  • Develop computational approaches to integrate MAP2K3 protein data with transcriptomic profiles

These advanced techniques will enable researchers to position MAP2K3 activation within the broader context of cellular signaling networks, providing insights into pathway crosstalk, feedback mechanisms, and heterogeneity in response to therapeutic interventions .